Version 1
: Received: 1 June 2023 / Approved: 2 June 2023 / Online: 2 June 2023 (03:49:55 CEST)
How to cite:
Seo, C. H.; Na, G. H.; Lee, D.; Park, J. H.; Hong, T. H.; Kim, O.-H.; Lee, S. C.; Kim, K.-H.; Choi, H. J.; Kim, S.-J. Pioneering PGC-1α-Boosted Secretome: A Novel Approach to Combating Liver Fibrosis. Preprints2023, 2023060120. https://doi.org/10.20944/preprints202306.0120.v1
Seo, C. H.; Na, G. H.; Lee, D.; Park, J. H.; Hong, T. H.; Kim, O.-H.; Lee, S. C.; Kim, K.-H.; Choi, H. J.; Kim, S.-J. Pioneering PGC-1α-Boosted Secretome: A Novel Approach to Combating Liver Fibrosis. Preprints 2023, 2023060120. https://doi.org/10.20944/preprints202306.0120.v1
Seo, C. H.; Na, G. H.; Lee, D.; Park, J. H.; Hong, T. H.; Kim, O.-H.; Lee, S. C.; Kim, K.-H.; Choi, H. J.; Kim, S.-J. Pioneering PGC-1α-Boosted Secretome: A Novel Approach to Combating Liver Fibrosis. Preprints2023, 2023060120. https://doi.org/10.20944/preprints202306.0120.v1
APA Style
Seo, C. H., Na, G. H., Lee, D., Park, J. H., Hong, T. H., Kim, O. H., Lee, S. C., Kim, K. H., Choi, H. J., & Kim, S. J. (2023). Pioneering PGC-1α-Boosted Secretome: A Novel Approach to Combating Liver Fibrosis. Preprints. https://doi.org/10.20944/preprints202306.0120.v1
Chicago/Turabian Style
Seo, C. H., Ho Joong Choi and Say-June Kim. 2023 "Pioneering PGC-1α-Boosted Secretome: A Novel Approach to Combating Liver Fibrosis" Preprints. https://doi.org/10.20944/preprints202306.0120.v1
Abstract
Liver fibrosis is a critical health issue with limited treatment options. This study investigates the potential of PGC-Sec, a secretome derived from PGC-1α-overexpressing adipose-derived stem cells (ASCs), as a novel therapeutic strategy for liver fibrosis. Upon achieving a cellular confluence of 70-80%, ASCs were transfected with pcDNA-PGC-1α. PGC-Sec, obtained through concentration of conditioned media using ultrafiltration units with a 3-kDa cutoff, was assessed through in vitro assays and in vivo mouse models. In vitro, PGC-Sec significantly reduced LX2 human hepatic stellate cell proliferation and mitigated mitochondrial oxidative stress compared to control-secretome (Ctrl-Sec). In an in vivo mouse model, PGC-Sec treatment led to notable reductions in hepatic enzyme activity, serum pro-inflammatory cytokine concentrations, and fibrosis-related marker expression. Histological analysis demonstrated improved liver histology and reduced fibrosis severity in PGC-Sec-treated mice. Immunohistochemical staining confirmed enhanced expression of PGC-1α, OPA1 (a mitochondrial function marker), and PPARα (an anti-fibrogenic marker) in the PGC-Sec-treated group, along with reduced Collagen 1A expression (a pro-fibrogenic marker). These findings highlight the therapeutic potential of PGC-Sec in combating liver fibrosis by enhancing mitochondrial biogenesis and function, and promoting antifibrotic processes. PGC-Sec holds promise as a novel treatment strategy for liver fibrosis.
Biology and Life Sciences, Biology and Biotechnology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
